{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:31:04Z","timestamp":1786336264452,"version":"build-2736575974"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Biochemical recurrence remains a clinically heterogeneous event in prostate cancer, yet the immune signals associated with relapse-prone tumors are not fully defined. This study investigated IL-27 and its receptor IL27RA as a potential immune\u2013epithelial ligand\u2013receptor axis linking microenvironmental inflammation, recurrence, and immune escape.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Transcriptomic and clinical datasets from TCGA and GEO were analyzed to assess IL-27 expression, biochemical recurrence-free survival, clinicopathological associations, immune infiltration, pathway activity, single-cell distribution, mutation features, and druggable-target patterns. Experimental validation was performed in RWPE-1 prostate epithelial cells and PC-3 prostate cancer cells using immunofluorescence staining, recombinant IL-27 stimulation, IL27RA knockdown, CCK-8 assays, and qRT-PCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Higher IL27 expression was observed in prostate cancer and was associated with recurrence, higher Gleason score, and shorter biochemical recurrence-free survival; the association with recurrence persisted after adjustment for the clinicopathological variables included in the Cox model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings identify IL27 expression as a recurrence-associated molecular feature in retrospective prostate cancer datasets and provide proof-of-concept evidence for an IL27RA-dependent response to IL-27 in PC-3 cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1931108","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:23:04Z","timestamp":1786335784000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["IL27 expression and IL27RA-dependent cellular responses are associated with biochemical recurrence and immune-regulatory features in prostate cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuliang","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Urology, The Fourth Affiliated Hospital of Anhui Medical University","place":["Chaohu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurui","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Fourth Affiliated Hospital of Anhui Medical University","place":["Chaohu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunhe","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Urology, The Fourth Affiliated Hospital of Anhui Medical University","place":["Chaohu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Ward 2 of Gastroenterology, Combined Ward of Rheumatology and Immunology, The Fourth Affiliated Hospital of Anhui Medical University","place":["Chaohu, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","article-title":"Epidemiology and genomics of prostate cancer in Asian men","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6941a1","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity - United States, 2001-2017","volume":"69","author":"Siegel","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000003892","article-title":"Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part I: Introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy","volume":"211","author":"Morgan","year":"2024","journal-title":"J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1181370","article-title":"The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma","volume":"14","author":"Yao","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1080\/1354750x.2026.2633567","article-title":"Prognostic value of circulating tumor DNA mutation panels to predict early recurrence and survival outcomes in early-stage breast cancer: a systematic review and meta-analysis","volume":"31","author":"Ali","year":"2026","journal-title":"Biomarkers"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2025.06.002","article-title":"Efficacy of pembrolizumab in MSI-high and BRCA-positive castration-resistant prostate cancer","author":"Higa","year":"2025","journal-title":"Cancer Genet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032414-112134","article-title":"The immunobiology of interleukin-27","volume":"33","author":"Yoshida","year":"2015","journal-title":"Annu Rev Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1074-7613(02)00324-2","article-title":"IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells","volume":"16","author":"Pflanz","year":"2002","journal-title":"Immunity"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8000","DOI":"10.3390\/ijms24098000","article-title":"Defective induction of IL-27-mediated immunoregulation by myeloid DCs in multiple sclerosis","volume":"24","author":"von Glehn","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2026.153214","article-title":"Interleukin 27 (IL-27) in gastrointestinal cancers: from dual roles in tumor immunity to immunotherapeutic opportunities","volume":"231","author":"Esmaeeli","year":"2026","journal-title":"Immunobiology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3958069","article-title":"Dual roles of IL-27 in cancer biology and immunotherapy","volume":"2017","author":"Fabbi","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2217\/imt.14.95","article-title":"The Yin and Yang aspects of IL-27 in induction of cancer-specific T-cell responses and immunotherapy","volume":"7","author":"Li","year":"2015","journal-title":"Immunotherapy"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-1628","article-title":"IL27 signaling serves as an immunologic checkpoint for innate cytotoxic cells to promote hepatocellular carcinoma","volume":"12","author":"Aghayev","year":"2022","journal-title":"Cancer Discov"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-21-1148","article-title":"Myeloid-derived suppressive cell expansion promotes melanoma growth and autoimmunity by inhibiting CD40\/IL27 regulation in macrophages","volume":"81","author":"Valencia","year":"2021","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.10.6527","article-title":"Antiproliferative activity of IL-27 on melanoma","volume":"180","author":"Yoshimoto","year":"2008","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.03.021","article-title":"Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy","volume":"345","author":"Liu","year":"2022","journal-title":"J Control Release"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1178025","article-title":"The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27","volume":"5","author":"d'Almeida","year":"2016","journal-title":"Oncoimmunology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01667-y","article-title":"Selective IL-27 production by intestinal regulatory T cells permits gut-specific regulation of T(H)17 cell immunity","volume":"24","author":"Lin","year":"2023","journal-title":"Nat Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1259336","article-title":"Cabozantinib and IL-27 combinatorial therapy for bone-metastatic prostate cancer","volume":"10","author":"Kumar","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neumar.2025.100077","article-title":"Identification of novel biomarkers and immune characteristics of spinal cord injury based on comprehensive bioinformatic analysis: A retrospective observational study","volume":"2","author":"Zha","year":"2025","journal-title":"NeuroMarkers"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2012.12.002","article-title":"IL-27 in tumor immunity and immunotherapy","volume":"19","author":"Murugaiyan","year":"2013","journal-title":"Trends Mol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/08830185.2020.1840565","article-title":"IL-27, a pleiotropic cytokine for fine-tuning the immune response in cancer","volume":"40","author":"Beizavi","year":"2021","journal-title":"Int Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/1354750x.2026.2630072","article-title":"Identification and validation of AFAP1L1 as an immune-related prognostic biomarker in clear cell renal cell carcinoma","volume":"31","author":"Yan","year":"2026","journal-title":"Biomarkers"},{"key":"B24","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","article-title":"Prostate cancer review: Genetics, diagnosis, treatment options, and alternative approaches","volume":"27","author":"Sekhoacha","year":"2022","journal-title":"Molecules"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.3390\/ijms24032185","article-title":"Biomarkers of aggressive prostate cancer at diagnosis","volume":"24","author":"Boehm","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-018-0060-7","article-title":"Landmarks in prostate cancer","volume":"15","author":"Sathianathen","year":"2018","journal-title":"Nat Rev Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.32900","article-title":"Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy","volume":"6","author":"Falagario","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216739","article-title":"Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts","volume":"588","author":"Yin","year":"2024","journal-title":"Cancer Lett"},{"key":"B29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2139\/ssrn.5297936","article-title":"The role of miR-10b-5p in prostate cancer and its exosome-mediated angiogenesis effect","author":"Wang","year":"2025","journal-title":"Cancer Genet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2025.117741","article-title":"Chronic NaAsO(2) exposure promotes migration and invasion of prostate cancer cells by Akt\/GSK-3beta\/beta-catenin\/TCF4 axis-mediated epithelial-mesenchymal transition","volume":"290","author":"Zhang","year":"2025","journal-title":"Ecotoxicol Environ Saf"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1931108\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:23:05Z","timestamp":1786335785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1931108\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1931108"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1931108","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1931108"}}